Ultragenyx Pharmaceutical vs Travere Therapeutics
RARE and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RARE and TVTX compare
Travere Therapeutics is the larger company, worth 3.0 times as much as Ultragenyx Pharmaceutical ($4.7B against $1.6B).
Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 17.5% for Ultragenyx Pharmaceutical).
Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −81.7% at Ultragenyx Pharmaceutical.
Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RARE | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $4.7B |
| Share price | $15.90 | $49.70 |
| Change, 1 year | −51.7% | 46.7% |
| Change, 5 years | −79.2% | 71.2% |
| Beta (5Y) | 2.20 | 1.95 |
| Employees | 1,371 | 497 |
| StockData Score | ||
| Total score | 9 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.2× (better) | 7.9× |
| P/B | – | 191× |
| EV/EBITDA | – | 192× |
| FCF yield | −31.2% | – |
| Fair value | – | $6.04 |
| Margin of safety | – | −723% |
| Growth | ||
| Revenue growth (TTM) | 17.5% | 77.1% (better) |
| Revenue growth, 5Y average | 19.9% (better) | 19.9% |
| Profitability | ||
| Gross margin | – | 98.6% |
| Operating margin | −73.6% | −6.8% (better) |
| Net margin | −81.7% | −7.4% (better) |
| FCF margin | −68.2% | – |
| Return on equity | – | −152% |
| Financial health | ||
| Interest coverage | – | −4.3× |
| Current ratio | 1.73 | 4.05 (better) |
| Altman Z-score | −5.29 | 2.19 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 108% | 112% |
| Held by insiders | 4.0% | 1.6% |
| Insider net buying, 12 months | −$3.8M (better) | −$110M |
| Short interest, % of float | 25.0% | 10.3% |
Go deeper
- RARE stock overview
- RARE income statement
- RARE valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.